An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX103 in Patients With X-Linked Retinoschisis (XLRS)
Latest Information Update: 24 Apr 2023
At a glance
- Drugs LX 103 (Primary)
- Indications Retinoschisis
- Focus Adverse reactions
Most Recent Events
- 24 Apr 2023 New trial record